Idexx Laboratories beat third-quarter forecasts and raised earnings guidance, sending shares up nearly 16% in morning trading. Adjusted earnings were $4.01 per share on $1.21 billion in sales, versus estimates of $3.73 and $1.19 billion. Sales grew 10% year over year, helped by pet health. Analysts flagged continued weakness in vet visits and consumer sentiment but cited growth accelerants in 2026 and 2027.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
